Repositioning Candidate Details
| Candidate ID: | R1517 |
| Source ID: | DB14059 |
| Source Type: | experimental; investigational |
| Compound Type: | small molecule |
| Compound Name: | SC-236 |
| Synonyms: | -- |
| Molecular Formula: | C16H11ClF3N3O2S |
| SMILES: | NS(=O)(=O)C1=CC=C(C=C1)N1N=C(C=C1C1=CC=C(Cl)C=C1)C(F)(F)F |
| Structure: |
|
| DrugBank Description: | SC-236 is a potent, selective, orally active inhibitor of cyclooxygenase-2 (COX-2) that has been studied in cancer therapy , lower back pain , and inflammation , ,, . |
| CAS Number: | 170569-86-5 |
| Molecular Weight: | 401.79 |
| DrugBank Indication: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | This drug is a selective inhibitor of the COX-2 enzyme , . COX-2 is expressed in the brain, in the kidney, in bone, and likely in the female reproductive system . Its expression at other sites is increased during inflammation, experimentally, in response to mitogenic stimuli. Growth factors, phorbol esters, and interleukin (IL)-1 stimulate the expression of COX-2 in fibroblasts, while endotoxin serves the same function in monocytes/macrophages . SC-236 works also directly through suppressing the nuclear translocation of RelA/p65, a transcription factor. SC-236 directly targets proteins that facilitate the nuclear translocation of NF-κB, an inflammatory signaling pathway , . |
| Targets: | Cyclooxygenase 2 inhibitor; Nuclear factor NF-kappa-B complex inhibitor |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|